Clinical Trials Logo

Papillomavirus Infections clinical trials

View clinical trials related to Papillomavirus Infections.

Filter by:

NCT ID: NCT05458869 Completed - Clinical trials for Human Papillomavirus Infection

Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma

Start date: September 6, 2022
Phase:
Study type: Observational

This study explores the human papillomavirus (HPV) self-collection experience among individuals with a history of sexual trauma. Cervical cancer is the fourth most common cancer in women worldwide and is the second leading cause of cancer-related death in women ages 29-39. Despite programs to improve accessibility of cervical cancer screening and overall high screening rates, disparities in routine surveillance have been demonstrated in certain populations, such as victims of intimate partner violence and sexual trauma. One barrier to participating in cervical cancer screening for this population is the office-based visit which necessitates the individual to undress, sit with their legs in stirrups, and undergo speculum examination for specimen collection. This type of visit may cause distress for participants who have experienced sexual violence. HPV self-collection has been studied with favorable outcomes in effectiveness and ease of use. This study evaluates the experience of HPV self-collection among individuals who have experienced sexual trauma.

NCT ID: NCT05435209 Completed - HPV Infection Clinical Trials

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

Start date: May 25, 2022
Phase: Phase 4
Study type: Interventional

The risk for Human Papillomavirus (HPV) infection persists through an individual sexual life and duration of protection is critical to vaccine effectiveness in protection from oncogenic hrHPV infection. HIV-infected individuals have an increased risk for HPV infection, and persistent infection. Most vaccine efficacy data among HIV-infected adolescents is represented by immunogenicity data, and there is little published literature on vaccine effectiveness as assessed by persistent incident genital HPV infection. Investigators shall re-enroll a cohort of previously vaccinated HIV-infected girls and boys for assessment of genital HPV infection 9-years post initial 3 doses of vaccination with quadrivalent HPV vaccine at ages 9 to 14 years.

NCT ID: NCT05372016 Completed - Cervical Cancer Clinical Trials

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Start date: September 19, 2020
Phase: Phase 3
Study type: Interventional

The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.

NCT ID: NCT05340322 Completed - HIV Infections Clinical Trials

Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and Telemedicine

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The Pocket colposcope has 510k FDA clearance and has been successfully used in almost 1500 unique patients globally in Duke and non-Duke protocols to date. The objective is to provide colposcopy capability to rural communities in Peru potentially using Telehealth. Approximately 10,000 women will receive self HPV test kit for community health workers. Of these participants, approximately 1,000 HPV+ participants will be invited to participate in this pocket colposcopy study. Approximately 500 of these participants may require treatment using thermocoagulation.

NCT ID: NCT05234112 Completed - HPV Infection Clinical Trials

Prevention and Screening Towards Elimination of Cervical Cancer

PRESCRIP-TEC
Start date: September 15, 2022
Phase: N/A
Study type: Interventional

The research project applies the protocol of the World Health Organisation for screening of cervical cancer, with testing of hrHPV as first screening, followed by Visual Inspection of the cervix with Acetic Acid for hrHPV-positive women and for women with minor lesions thermo-ablation of affected areas. This procedure is applied in Uganda, India and Bangladesh. In Slovakia hrHPV-positive women are offered Pap-smear and for women with Pap IV lis excision.

NCT ID: NCT05175482 Completed - Health Behavior Clinical Trials

Health Belief Model Based Education on Human Papilloma Virus Infection and Vaccination

Start date: December 30, 2021
Phase: N/A
Study type: Interventional

To evaluate impact of Health Belief Model Based Education on Human Papilloma Virus Infection and Vaccination among University Students

NCT ID: NCT05156541 Completed - Clinical trials for Human Papillomavirus Infection

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts

ING-HPV-1
Start date: May 18, 2009
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.

NCT ID: NCT05119855 Completed - Clinical trials for Papillomavirus Infections

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Start date: March 28, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus nonconcomitant administration of 9vHPV and mRNA-1273 vaccines in boys and girls 9 to 11 years of age.

NCT ID: NCT05109533 Completed - HPV Infection Clinical Trials

Probiotics Role in HPV Cervico-vaginal Infection Clearance

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Vaginal infections demonstrated to be implicated in the persistence of HPV, activating a vicious circle of vaginal microbial perturbations. HPV infection can destroy the biofilm barrier formed by the local vaginal immune microenvironment, leading to a condition called dysbiosis. Contemporarily, the resulting local microecological imbalance in the vagina can subsequently upregulate the expression of the HPV protein, increasing HPV-related cytological alterations.

NCT ID: NCT05078554 Completed - Clinical trials for Papilloma Viral Infection

HPV and Male Homosexuality in General Practice?

HPV
Start date: May 27, 2021
Phase:
Study type: Observational

The main objective of this study is to find out whether young MSM (men who have sex with men) believe it is important for their GP to be informed of their sexual orientation, in order to improve their clinical, especially with HPV vaccination. The secondary objective is to analyze the state of knowledge about the HPV vaccine and the value of HPV vaccine in this target population.